Skip to main content
EYPT
NASDAQ Industrial Applications And Services

EyePoint Q2 Loss Widens to $94.5M; LUGANO Wet AMD Data Due This Month, Cash Runway into Q4 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$11.816
Mkt Cap
$978.428M
52W Low
$9.4
52W High
$19.11
52W Position info
26% above low
Off High info
38% below high
Rel. Volume info
2.2× avg
Market data snapshot near publication time

EYPT sits 26% above its 52-week low of $9.4 on elevated volume (2.2× avg).

Summary

EyePoint's Q2 loss ballooned to $94.5M as it advances DURAVYU toward pivotal data. LUGANO wet AMD results are expected this month, with $180M in cash providing runway into Q4 2027.


Key Events · Earnings and Guidance · EYPT

  • Q2 Net Loss Widens to $94.5M

    Net loss reached $94.5 million ($1.09/share) vs. $59.4 million a year ago, driven by a 48% jump in R&D expenses to $83.6 million for DURAVYU Phase 3 trials and manufacturing scale-up.

  • LUGANO Wet AMD Data Imminent

    Topline results from the pivotal Phase 3 LUGANO trial in wet AMD are expected in August 2026, with the LUCIA trial to follow in Q4 2026. Over 900 patients are enrolled across both studies.

  • Cash Runway into Q4 2027

    Cash and investments totaled $180 million as of June 30, 2026, down from $223 million at March 31, 2026. Management expects this to fund operations into Q4 2027, beyond the LUGANO and LUCIA readouts.

  • DME Trials Fully Enrolled

    The COMO and CAPRI Phase 3 DME trials completed enrollment of over 480 patients in five months, with topline data anticipated in Q4 2027.


Analysis · EYPT · Industrial Applications And Services

EyePoint reported a steep Q2 net loss of $94.5 million, up from $59.4 million a year ago, as R&D spending surged for its DURAVYU Phase 3 programs. The company holds $180 million in cash, funding operations into Q4 2027 — past the expected LUGANO topline data this month and LUCIA data in Q4 2026. With LUGANO results imminent, the readout is a binary event that could validate DURAVYU's potential in the $15B+ wet AMD market or raise doubts about the program. The full enrollment of the DME trials and the appointment of a Chief Strategic Science Officer add to the narrative of a company at a critical inflection point.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EYPT was trading at $11.82 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $978.4M. The 52-week trading range was $9.40 to $19.11. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EYPT - Latest Insights

EYPT
Nov 12, 2026, 4:05 PM EST
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.350
Real-time Price: $0.3039 info
Change: -$0.0461 (-13%) info
Market Cap: $34.817M info
EYPT
Nov 12, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.3039 info
Change: -$0.0561 (-16%) info
Market Cap: $34.817M info
EYPT
Nov 12, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.360
Real-time Price: $0.3039 info
Change: -$0.0561 (-16%) info
Market Cap: $34.817M info
EYPT
Oct 19, 2026, 9:22 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.5443
Real-time Price: $0.3039 info
Change: -$0.2404 (-44%) info
Market Cap: $34.817M info
EYPT
Oct 19, 2026, 8:08 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $0.6115
Real-time Price: $0.3039 info
Change: -$0.3076 (-50%) info
Market Cap: $34.817M info